Tecartus Approval History
FDA Approved: Yes (First approved July 24, 2020)
Brand name: Tecartus
Generic name: brexucabtagene autoleucel
Dosage form: Suspension for Intravenous Infusion
Previous Name: KTE-X19
Company: Kite, a Gilead Company
Treatment for: Mantle Cell Lymphoma
Tecartus (brexucabtagene autoleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
Development History and FDA Approval Process for Tecartus
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.